The efficacy of everolimus and sunitinib in patients with sporadic or germline mutated metastatic pancreatic neuroendocrine tumors

BACKGROUND: Hyperactivation of mTOR pathway and angiogenesis have been implicated in the pathogenesis of neuroendocrine tumors (NETs). Everolimus, an oral inhibitor of mTOR, and sunitinib, an antiangiogenic drug, are effective targeted therapies approved to treat locally advanced/metastatic pancreat...

Full description

Saved in:
Bibliographic Details
Published in:J Gastrointest Oncol
Main Authors: Nuñez, Jose Eduardo, Donadio, Mauro, Filho, Duilio Rocha, Rego, Juliana Florinda, Barros, Milton, Formiga, Maria Nirvana, Lopez, Rossana, Riechelmann, Rachel
Format: Artigo
Language:Inglês
Published: AME Publishing Company 2019
Subjects:
Original Article
Online Access:https://ncbi.nlm.nih.gov/pmc/articles/PMC6657324/
https://ncbi.nlm.nih.gov/pubmed/31392045
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.21037/jgo.2019.01.33
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items